September 2020 - Page 2 of 2 - TransparentRx
Skip to content
TRX_LOGO-01-white
  • About
  • Members
    • Member Portal
    • Member Portal Tutorial
    • Discount Rx Card
    • FAQs
    • Formulary
    • Mail Registration Form
    • Prior Authorization
    • Reimbursement Form
  • Clients
    • Case Study
    • CPBS Certification
    • DIY Data Analytics
    • Fiduciary PBM
    • Get a Quote
    • Savings Calculator
    • Self-Assessment
    • Transition Guide
    • White Papers
  • Events
  • Blog
  • Contact Us
  • (866) 499-1940
Menu Close

Monthly Archives: September 2020

Home » Archives for September 2020 » Page 2

Tuesday Tip of the Week: 6 Reasons a Small PBM is as Good as a Big PBM

  • Post author:Tyrone Squires, MBA, CPBS
  • Post published:September 2, 2020
  • Post comments:0 Comments
  • Go to the previous page
  • 1
  • 2

ABOUT THE AUTHOR

Tyrone Squires, CPBS is author of The Employer’s Guide Blog to Overseeing PBMs. Mr. Squires is Founder and Managing Director of TransparentRx , the first fiduciary model PBM, and lead lecturer for the Certified Pharmacy Benefits Specialist (CPBS) program. A course which offers, SHRM, HRCI, pharmacists and L&H licensees up to 20 hours of continuing education. Read More.

Subscribe to Blog

Email


Subscribe to Newsletter




Aticles By Date

2025 (39)
January (6)
  • FTC Second Interim Staff Report Finds PBMs Charge Significant Markups [News Roundup]
  • How Self-Insured Employers Can Optimize PBM Contract Negotiations
  • Medicare Coverage of Anti-Obesity Medications [News Roundup]
  • Understanding PBM Fiduciary Duty
  • Drugmakers to hike US prices of over 250 branded medications [News Roundup]
  • The Four Pillars of Pharmacy Costs—and How to Master Them
February (6)
  • PBM Performance Metrics You Can’t Afford to Ignore
  • DAW 9: The Hidden PBM Scheme Costing You Millions—Shut It Down Now
  • Fiduciary duty claims in prescription drug case dismissed [News Roundup]
  • Mastering PBM Procurement to Control Costs and Maximize Value: A Guide for Directors of Benefits
  • PBM hit with $10 million verdict in price-fixing arbitration [News Roundup]
  • AI in Pharmacy Benefits: A Game-Changer or a Risky Gamble for Employers?
March (6)
  • PBM “Lesser of Logic”: What It Is, How It’s Used, and What to Do About It
  • Five ways to improve PBM procurement for clients [News Roundup]
  • Winning Strategies for Plan Sponsors to Reduce Medical Benefit Drug Costs
  • Merck Lowered the Price of Januvia—Insurers Dropped It from Formularies [News Roundup]
  • How to Compare PBM Proposals and Avoid Costly Mistakes
  • The Benefits and Challenges of Subcutaneous Infusion in Cancer Care [News Roundup]
April (6)
  • The Future of Pharmacy Networks: Practical Advice for Employers
  • Executive Action Aims to Slash Drug Prices and Enhance PBM Clarity [News Roundup]
  • Six Pillars of a High-Performing Pharmacy Benefit Plan Design
  • Governor signs legislation banning PBMs from simultaneously owning pharmacies [News Roundup]
  • 5 “Innocent” PBM Contract Clauses That Can Cost You Big
  • The Rise in Direct-to-Consumer Advertising of Prescription Drugs [News Roundup]
May (8)
  • Private Equity Firms Gobbling Up Health Care Facilities at a Skyrocketing Pace [News Roundup]
  • If I Were Starting Over as a Pharmacy Benefits Buyer, This Is What I’d Do
  • Patients Taking Newer Weight Loss Drugs Likely to Return to Their Original Weight Within 2 Years, Study Says [News Roundup]
  • Unlocking the Secrets of PBMs: Strategies to Navigate Their Profit Tactics (Volume 93)
  • As Rite Aid collapses, customers and other pharmacies bear the impact [News Roundup]
  • How HR and Finance Leaders Can Take Control of Soaring GLP-1 Drug Costs
  • Why You Should Care How Much Your PBM Makes
  • Self-Funded Health Plans and Recent Challenges to State PBM Laws [News Roundup]
June (7)
  • CMS Head Urges PBMs to End Drug Rebates [News Roundup]
  • What Budget Airlines Can Teach Us About PBMs
  • The Perfect Timetable for PBM RFPs
  • FTC Issues Warning on Rebates That Block Lower-Cost Drugs [News Roundup]
  • The Missing Piece in HR’s Benefits Strategy: An Internal Pharmacy Benefit Team
  • 83% of Americans Unwilling to Pay More Than $100 for GLP-1s, Survey Shows [News Roundup]
  • If Your PBM Offers Point Solutions But No One Uses Them, What’s the Point?
2024 (81)
January (4)
  • Tyson Foods, Employing 140,000, Parts Ways with Major PBM [Weekly Roundup]
  • Navigating the Shift of J-Code Drugs to Pharmacy Benefits: A Comprehensive Analysis
  • 5 ways to improve your PBM procurement process in 2024 [Weekly Roundup]
  • Medication Therapy Management (MTM) Expansion: CMS Takes Major Steps as Self-Funded Employers Remain Inactive
February (6)
  • Leveraging Data Analytics in PBM: A Strategic Imperative for Decision Makers
  • Copay Adjustment Programs: What’s Next for Manufacturers? [Weekly Roundup]
  • Weight Loss Drug Coverage Dilemma: Corporate Strategies and Healthcare Implications
  • Unlocking the Value of Pharmacy Benefits: The Essential Qualities of a Top-Tier Consultant
  • Best Pharmacy Benefit Consultants for Cost-Effective Drug Plans [Weekly Roundup]
  • Breaking: Employees Hit Johnson & Johnson with a Major Lawsuit Over Sky-High Drug Costs
March (8)
  • Formularies Through the Lens of Pharmaceutical Manufacturers: Impacts on Rebates
  • AI-Driven Solutions Promote Medication Adherence [Weekly Roundup]
  • Optimizing Medication Adherence with Advanced Pharmacy Benefit Management for HR and Finance Leaders
  • Study: Utilization management has ramped up in Part D over past decade [Weekly Roundup]
  • PBM Analytics: Essential KPIs for CHROs
  • The Risks of Relying on Self-Professed Pharmacy Benefit Experts and the Value of Certification
  • ERISA’s Cure for the $1.5 Trillion Health Benefits Market [Weekly Roundup]
  • Strategies Pharmaceutical Companies Use to Maximize Profits on Drugs
April (5)
  • Revolutionizing Pharmacy Benefits by Disrupting the Status Quo and Driving Down Costs, Watch On-Demand
  • Pharmacy Benefit Design: Navigating the Nuances through Comparative Analysis
  • Reviewing PBM Alternative Pricing Models for CVS Health, ESI, and OptumRx [Weekly Roundup]
  • Price is Not Cost: Understanding the Real Drivers Behind Pharmacy Benefit Expenses
  • Mayo Clinic Employee Files Class Action Lawsuit Over High Health Care Costs [Weekly Roundup]
May (7)
  • Understanding the Consolidated Appropriations Act (CAA) for Pharmacy Benefit Management
  • Mastering PBM Negotiations with Effective Strategies for Employers and Benefits Consultants
  • Evaluation of Top 10 Pharmacy Benefit Manager Clinical Programs
  • New Lawsuit Targets Opioid Pharmacy Benefit Managers [Weekly Roundup]
  • The Vital Role of Information Technology Department in PBM Industry
  • Top Ten Pharmacy Benefit Manager Utilization Management Programs
  • Audit of the American Postal Worker’s Union Health Plan’s Pharmacy Operations [Weekly Roundup]
June (6)
  • Employer Coverage of GLP-1 Drugs Jumps [Weekly Roundup]
  • New York Times ‘The Opaque Industry Secretly Inflating Prices’: A Fiduciary PBM’s Perspective
  • The J&J lawsuit should be a wakeup call to the PBM industry — and to companies everywhere [Weekly Roundup]
  • How ERISA Fiduciary Responsibility Sets CAA-Compliant PBMs Apart
  • Sanofi and Bristol Myers on the hook for $916M in do-over of Plavix marketing case [Weekly Roundup]
  • I’m Worried! Triple Agonist GLP-1 Retatrutide is on the Way
July (7)
  • Webinar: Unlocking the Secrets of PBMs Strategies to Navigate Their Profit Tactics
  • Prescription Rebate Guarantees: Employer Insights [News Roundup]
  • Why HR Should Become Experts in Pharmacy Benefit Management
  • How Pharmacy Benefit Managers Outsmart Regulators [Weekly Roundup]
  • The Importance of Hiring Certified Consultants and Brokers
  • The path to cheaper prescription drugs runs through PBMs [Weekly Roundup]
  • Understanding the Venn Diagram for Pharmacy Benefits Management
August (8)
  • Chairman Comer Calls on PBM Executives to Correct Hearing Testimony [News Roundup]
  • Understanding the Impact of the 340B Program on Commercial Contracts
  • Three Things That Employer Health Plan Sponsors Should Do When the New MHPAEA Rules Are Published [News Roundup]
  • DIR Fees: Understanding the Impact on Your Pharmacy Benefit Strategy
  • 3 Trends Reshaping Pharmacy Benefits Management [News Roundup]
  • Designing a Pharmacy Benefit Management Program to Reduce FWA and Improve Patient Outcomes
  • Here we go again: Class action against Wells Fargo alleges fiduciary breach and mismanagement of prescription drug plan [News Roundup]
  • Navigating the Consolidated Appropriations Act: What Self-Funded Plans Need to Know
September (8)
  • Employers seeking to avoid cost-shifting even as expenses continue to rise [News Roundup]
  • FTC Complaint Targets PBM Practices: What Self-Insured Employers and Benefit Consultants Need to Know
  • Pharmaceutical Strategies Group Publishes 2024 Pharmacy Benefit Manager Customer Satisfaction Report [News Roundup]
  • Express Scripts Sues FTC, Demands Withdrawal of PBM Report [News Roundup]
  • Unlocking the Secrets of PBMs Strategies to Navigate Their Profit Tactics (Volume 89)
  • Maximizing Benefits with Rebate Aggregators and PBM-Owned GPOs: A Comprehensive Guide for Employee Benefit Brokers, HR Executives, and CFOs
  • Walgreens will pay $106.8 million to settle claims of fraudulently billing U.S. government for undispensed prescriptions [News Roundup]
  • Understanding Formulary Position: A Simple Guide for Employers and Brokers
October (10)
  • The Need for Regulation to Positively Impact Drug Formulary Decisions [News Roundup]
  • The Pulse of the Purchaser Fall 2024 Survey: Five Key Takeaways for Self-Insured Employers
  • Copay Adjustment Programs: What Are They and What Do They Mean for Consumers? [News Roundup]
  • Three Key Considerations for Specialty Pharmacy Benefits Management: Price, Clinical Appropriateness, and Drug Mix
  • ‘Biosimilar’ drugs are gaining market share, Tufts researchers find [News Roundup]
  • The Hidden Costs of Multiple MAC Lists in PBM Practices
  • Supreme Court takes up PBM case: Does ERISA preempt states’ efforts to regulate drug prices? [News Roundup]
  • Unlocking the Secrets of PBMs: Strategies to Navigate Their Profit Tactics (Volume 90)
  • What Went Wrong: How Formularies, Contracts, and Rebates Created a Headwind for Biosimilars [News Roundup]
  • Maximizing Cost Efficiency and Control: Moving J Code Drugs from Medical to Pharmacy Benefit
November (5)
  • How Data is Revolutionizing Medical and Pharmacy Benefit Decisions
  • The Inflation Reduction Act’s Implications for Employer-Sponsored Health Plans [News Roundup]
  • Specialty Dispensing Rate (SDR): Introducing a New Metric for Managing Pharmacy Benefits and Costs
  • Barron’s Exposé Details the Role of PBMs in Possibly Fueling the Opioid Crisis [News Roundup]
  • Is Your Pharmacy Benefit Delivering Maximum Value? Unpacking the Complexity of Formulary Management
December (7)
  • How Accumulator Programs Exploit Patients and Drive-Up Medical Costs [News Roundup]
  • The Real Problem with PBM Spread Pricing
  • How a Duty to Spend Wisely on Worker Benefits Could Loosen PBMs’ Grip on Drug Prices [News Roundup]
  • How Pharmacy Benefit Managers Leverage Data Analytics – A Must-Read Q&A
  • Proposed Legislation Targets Pharmacy Benefit Managers, Calls for Pharmacy Divestiture [News Roundup]
  • Take Back Control: Navigating PBM Profit Tactics with Confidence
  • PBM Contracting and Administration: What Are the Rules of the Road for Self-Insured Employers? [News Roundup]
2023 (77)
January (6)
  • Navigating ERISA Compliance for Employer-Sponsored Pharmacy Benefits
  • Why Now Is the Time for Health Plans to Take Control of Pharmacy Benefits [Weekly Roundup]
  • 10 Benchmarks of PBM Pricing
  • Drug companies favor biotech meds over pills, citing new U.S. law [Weekly Roundup]
  • 8 Reasons You Need a Fiduciary PBM
  • Lawsuit accuses former executives of failing in fiduciary duty to oversee PBM operations [Weekly Roundup]
February (9)
  • How PBMs Make Money And What to Do About It [Free Webinar]
  • PSAOs Primed to Unlock Specialty Payor Contracts [Weekly Roundup]
  • 10 Things to Know About Biosimilar Drugs
  • Employer-sponsored plans pay up to 3,350 percent higher than Medicare for commonly used medications [Weekly Roundup]
  • Federal Judge Rules Cheaper Drugs Can Be Imported From Canada [Weekly Roundup]
  • 10 Ways Employers Can Effectively Manage the Cost of Specialty Drugs
  • What Johnson & Johnson’s Lawsuit Against SaveOnSP Means for Drug Manufacturers and Plan Sponsors [Weekly Roundup]
  • Unpacking the Concept of Pass-Through Pharmacy Benefit Managers: Benefits and Challenges
  • Chelsea Handler ‘Didn’t Know’ She Was on Ozempic [Weekly Roundup]
March (6)
  • Ohio attorney general sues pharmacy benefit managers, calling them ‘gangsters,’ [Weekly Roundup]
  • Study Sheds Light on Concerning New Trend in Drug Advertising [Weekly Roundup]
  • Self-insured employer gets hit with $50 million in claims for just two members
  • The List of PBM Formulary Exclusions Grew in 2023 [Weekly Roundup]
  • Drugmakers circumvent health plan sponsors’ benefit designs at the switch to have expensive brand pharmaceuticals dispensed
  • Top Threats and Priorities in Employer-Sponsored Health Plan Benefits [Weekly Roundup]
April (6)
  • Study Reveals Factors That Dissuade Commercial Plans From Covering Biosimilars [Weekly Roundup]
  • The Hidden Savings: How Choosing a Fiduciary PBM Could Revolutionize Your Healthcare Benefits
  • 3 Digital Health Strategies to Improve Health Plan Member Experience [Weekly Roundup]
  • Maximizing Employee Health and Reducing Healthcare Costs: Incorporating Medication Therapy Management into Self-Insured Employer Health Programs
  • Biosimilars Are Mighty, Can Help Alleviate Drug Spend Cost Burden [Weekly Roundup]
  • Optimizing Medication Therapy: How Pharmacogenomics Benefits Self-Insured Employers
May (8)
  • The Consolidated Appropriations Act and PBM Transparency [Weekly Roundup]
  • PBM Carve-Out Gives Employers More Control and Flexibility
  • Report: “Specialty” drugs are by far the most expensive, but classification seems arbitrary [Weekly Roundup]
  • Uncovering Overcharges in Pharmacy Benefit Management: Three Key Indicators
  • Major Trends in the 2023 Specialty Therapy Pipeline [Weekly Roundup]
  • Dispelling the Myth: Does Size Really Matter When It Comes to Pharmacy Benefit Managers and Cost Savings?
  • 2023 Trends in Specialty Drug Benefits Report Released by PSG [Weekly Roundup]
  • Self-Insured Employer Strategies for Optimizing Pharmacy Benefit Plan Design
June (8)
  • Playbook for Employers – Addressing PBM Misalignment [Weekly Roundup]
  • 8 Advantages of a Professional Certification in Employee Benefits
  • The Market Demands Transparency and Perhaps a Whole Lot More [Weekly Roundup]
  • A Guide to Identifying a Pass-Through Pharmacy Benefit Manager (PBM)
  • Site-of-Care Shock Looms for Infusion Services [Weekly Roundup]
  • Demystifying PBM Pricing and Unveiling the Truth Behind Pharmacy Benefit Manager Costs [Free Webinar]
  • Employers’ New Decision Point: Whether to Cover Expensive Weight Loss Drugs [Weekly Roundup]
  • Statement of Ethics for the Certified Pharmacy Benefits Specialist (CPBS) Program
July (7)
  • Annual Report on Specialty Spend and Trends [Weekly Roundup]
  • How PBM Data Analytics Platform Solutions Enhance Medical and Pharmacy Benefit Programs
  • How Self-Funded Employers Can Use Point Solutions to Manage Pharmaceutical Costs [Weekly Roundup]
  • Federal Trade Commission Votes to Release Statement Retracting Previous Advocacy on Pharmacy Benefit Managers
  • FTC Reverses Course on Previous Endorsement of Pharmacy Benefit Intermediaries [Weekly Roundup]
  • CAA-Compliant Checklist for HR Leadership Teams
  • PBM Key Performance Indicators (KPIs) Every HR Leader Should Know
August (4)
  • Employers would like to see changes spread to the business sector as prescription costs climb [Weekly Roundup]
  • Prior Authorization (PA): Take It Out of the Hands of Non-Fiduciary PBMs
  • The Transformation of Blue Shield of California’s Prescription Drug Model: What’s Behind It? [Weekly Roundup]
  • Creating an Effective PBM Formulary: 10 Key Mistakes to Dodge for Enhanced Patient Care and Cost Savings
September (6)
  • ICER Updates Assessment Framework to Include New Measures of Value [Weekly Roundup]
  • eVouchers Circumvent Benefit Designs to Get High-Cost Brand Drugs Dispensed [Rerun]
  • Satisfaction With Pharmacy Benefits Managers Hits 9-Year Low [Weekly Roundup]
  • A Holistic Approach to Drug Therapy Optimization for Employers and Patients
  • CEO thinks more payers will leave traditional PBMs behind [Weekly Roundup]
  • Drug Utilization Management Programs: Exploring Benefits and Challenges
October (5)
  • Pharmacy Benefit Questions to Ask for HR
  • Copay Accumulators: Implications for PBMs and Health Plans After Court Strikes Down HHS Rule [Weekly Roundup]
  • Unlocking the Power of Net Promoter Score (NPS) in the PBM Industry
  • Employers take tougher measures because of rising health costs [Weekly Roundup]
  • Trends in Compensation of PBMs and PBM Contracting Entities
November (8)
  • Hospitals are dropping Medicare Advantage plans left and right [Weekly Roundup]
  • PBM Copay Accumulator Programs: Employers Must Prepare for Changes
  • PBMs Should Brace for a Copay Accumulator Program Shift [Weekly Roundup]
  • Pharmacy Benefit Institute of America Celebrates Outstanding Achievements of New CPBS Graduates
  • Plan Sponsors Have a Fiduciary Duty to Employees that Includes Scrutiny of PBM-Owned Rebate Aggregators [Weekly Roundup]
  • 5 Strategies for Employers to Address Social Determinants of Health (SDOH)
  • Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy [Weekly Roundup]
  • TransparentRx Recognized in the Prestigious 7th Annual Vet100 List
December (4)
  • Employer Health Plans Fear State PBM Crackdown Preemption Threat [Weekly Roundup]
  • Navigating the Waters of Stop-Loss Insurance
  • CMS Letter to Pharmacy Benefit Management Companies [Weekly Roundup]
  • Outcomes-Based Rebates in Pharmaceuticals: Essential Insights for Employee Benefit Brokers
2022 (121)
January (12)
  • Billionaire Mark Cuban steps up assault on US prescription drug prices, or is he just another player in the mail-order pharmacy market? [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 398)
  • Tip of the Week: eVouchers help circumvent health plan sponsor benefit designs to get high-cost brand drugs dispensed
  • Issues Arise as Health Plans Begin Covering At-Home COVID-19 Tests [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 397)
  • Tip of the Week: Why Ignoring Small PBMs Will Cost Self-Insured Employers Time and Money
  • The Case Against Excluding Specialty Drug Coverage [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 396)
  • The Chief Medical Officer for CVS Caremark Said What?!
  • CMS Plans to Regulate Pharmacy Benefit Manager DIR Fees [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 395)
  • Tip of the Week: Copay Accumulator Programs are Bad for Business
February (11)
  • New study claims hospitals charge double for specialty drugs compared to pharmacies [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 402)
  • Every Health Care Plan Sponsor Must Have a System in Place to Make Sure Drugs Work [Tip of the Week]
  • How Pharmacy Benefit Managers Make Money and What To Do About It [Free Webinar]
  • New Exposé Reveals Pharmacy Benefit Manager Tactics That Hurt Patients, Providers, Employers, and Taxpayers [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 401)
  • PBMs ranked by market share: CVS Caremark is No. 1 [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 400)
  • 4 Little Known Ways to Optimize Drug Spend [Tip of the Week]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 399)
  • How Pharmacy Benefit Managers Make Money and What To Do About It [Free Webinar]
March (6)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 405)
  • How Pharmacy Benefit Managers Make Money and What To Do About It [Free Webinar]
  • 5 Best Methods to Counter Fraud, Waste and Abuse in Pharmacy Benefits
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 404)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 403)
  • Copayment coupons are adding to pharmacy costs [Tip of the Week]
April (12)
  • Copay Coupons Charity or a Bribe? [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 409)
  • PBM Formulary Management Tips: Three That Are Meaningful
  • Court Rules in Favor of Cigna Over Anthem in $14.8B PBM Drug Overcharge Claim [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 408)
  • Prior Authorization for Prescription Drugs What You Should Now
  • Average Wholesale Price (AWP) 3 Reasons Why It is Misunderstood
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 407)
  • Court Rules in Favor of Cigna Over Anthem in $14.8B PBM Drug Overcharge Claim
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 406)
  • PBM Performance Guarantees are Meaningless Unless Constituent Elements are Spelled Out [Tip of the Week]
  • Key Differences Between Fiduciary and Traditional PBM Business Models [Weekly Roundup]
May (14)
  • How Pharmacy Benefit Managers Make Money and What to Do About It [Free Webinar]
  • Anti-competitive PBM Practices Harming Patients, Payers, and Pharmacies, APCI Tells FTC [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 413)
  • 6 PBM Performance Metrics to Hang Your Hat On
  • CMS Medicaid Copay Rule Struck Down by Federal Judge, Handing Drugmakers Major Win [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 412)
  • 5 Questions to Ask PBM Finalists Before Announcing the Winner of a Competitive Bidding Process
  • Trends in Specialty Benefit Design Report Published by PSG [Weekly Roundup]
  • Generic Substitution Rate (GSR) and Employer-Sponsored Prescription Drug Costs
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 411)
  • Johnson and Johnson sues SaveOnSP for allegedly overusing drug cost assistance program [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 410)
  • How PBMs Make Money and What To Do About It [On-Demand Video]
  • How Pharmacy Benefit Managers Make Money and What to Do About It [Free Webinar]
June (13)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 418)
  • Prescription Drug Pricing Isn’t The Problem. Bloomberg Law Has It Wrong.
  • Formulary Steering Prevents Members from Accessing Generics [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 417)
  • How Pharmacy Benefit Managers (PBM) Make Money
  • The Future of Employer Sponsored Healthcare Plans Is Cost Management [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 416)
  • PBM Formulary Management Tips: Three That Are Meaningful [Rerun]
  • 6 Payor Tactics to Control Drug Spending [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 415)
  • Benefits of Working with a Fiduciary Model PBM [Free Webinar]
  • 6 Payor Tactics to Control Drug Spending [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 414)
July (14)
  • Pharmacogenomics is Increasingly Relevant [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 422)
  • Is Drug Importation a Valid Prescription?
  • Doctors use more brand drugs when on the pharma dole [Weekly Roundup]
  • Simplifying Medical Benefit Drug Management Complexities [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 421)
  • 5 Things To Do Immediately About Drivers Of Pharmacy Costs
  • How specialty drug ‘solution stacking’ can rein in pharmacy benefit costs [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 420)
  • Three Reasons Why the PBM Transparency Act Won’t Reduce Drug Costs
  • Florida Takes Additional Actions to Lower Prescription Drug Prices [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 419)
  • “Big Three” PBM and National Association of Chain Drug Stores (NACDS) Part Ways
  • 300 drugs now in generic ‘cartel’ probe [Weekly Roundup]
August (9)
  • Is self-funding the solution to growing medical and drug costs? [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 426)
  • Newly launched U.S. drugs head toward record-high prices [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 425)
  • Pharmacy Benefit Managers Falsely Use DAW Codes
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 424)
  • Biosimilars shake up US drug market in 2023 and beyond [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 423)
  • How Pharmacy Benefit Managers Make Money and What to Do About It [Free Webinar]
September (9)
  • Three Underappreciated Reasons for Micromanaging Pharmacy Benefits
  • How PBMs Make Money and What to Do About It [Free Webinar]
  • 2023 Large Employers’ Health Care Strategy and Plan Design Survey [Weekly Roundup]
  • The Conventional PBM RFP Process Is Flawed – Here’s the #1 Way to Fix It
  • PBM Ordered to Pay Aids Healthcare Foundation (AHF) $23 million [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 428)
  • 6 Indicators Your PBM is Hoarding Rebates
  • 4 PBM Trends to Watch — And, Yes, Transparency is One of Them [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 427)
October (6)
  • 6 Things Every Transparent PBM Should Do for Clients
  • How the 10 largest PBMs hold huge sway in health care marketplace [Weekly Roundup]
  • New Report Clears Up Misunderstandings About Drug Pricing Benchmarks
  • Learn How PBMs Make Money
  • New inflation-linked drug rebates have gone into effect [Weekly Roundup]
  • 4 questions to ask before signing your next PBM service agreement [Weekly Roundup]
November (7)
  • FDA Approves $3.5 Million Gene Therapy to Treat Adults with Hemophilia B
  • What do Ticketmaster and Pharmacy Benefit Managers have in common? [Weekly Roundup]
  • FTC reaffirms commitment to unfair business practices
  • Consolidated Appropriations Act shifts more responsibility to employers next year [Weekly Roundup]
  • PBM Revenue Streams that are Bad for Customers
  • How PBMs Make Money and What to Do About It [Free Webinar]
  • Get ready for hemophilia gene therapies at $2M-$3M [Weekly Roundup]
December (8)
  • How Coupons Keep Drugs Costly [Weekly Roundup]
  • Ask PBMs These 8 Questions
  • Americans are Becoming Sicker Because of Rising Prescription Drug Costs [Weekly Roundup]
  • 6 Indicators Your PBM is Hoarding Rebates [Rerun]
  • Self-funded plans sue health care company alleging overcharging and other ERISA violations [Weekly Roundup]
  • How PBMs Make Money and What to Do About It [Free Webinar]
  • Type 2 Diabetes Drug is Hollywood’s Latest Diet Craze [Weekly Roundup]
  • 5 Metrics Every PBM Should Be Measured By
2021 (128)
January (7)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 350)
  • [Free Webinar] The Untold Truth: How Pharmacy Benefit Managers Make Money
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 349)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 348)
  • Tuesday Tip of the Week: It is a Myth That Any Pharmacy Benefit Manager Offers Better Price Savings Because of Their Size
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 347)
  • Tuesday Tip of the Week: Expanded Drug Lists are an Excessive Pharmacy Cost Driver
February (9)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 354)
  • Tuesday Tip of the Week: 3 Ways Savings Could be Achieved by Improving Pharmacy Benefit Design and Management (Rerun)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 353)
  • Tuesday Tip of the Week: Optimize Specialty Contracting to Control Costs and Improve Patient Outcomes
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 352)
  • Tuesday Tip of the Week: Money is Good, Information is Better
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 351)
  • Auditor Claims Non-Fiduciary Pharmacy Benefit Manager Hiked Drug Prices by $1.6 million with Rebate Credit Program
  • Tuesday Tip of the Week: Drug Manufacturer Rebates Have Never Been the Problem
March (11)
  • Tip of the Week: Pass-Through and Transparent PBM Business Models are Small Ideas (Re-run)
  • [Free Webinar] The Untold Truth: How Pharmacy Benefit Managers Make Money
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 358)
  • Tuesday Tip of the Week: It is a Myth That Any Pharmacy Benefit Manager Offers Better Price Savings Because of Their Size (Rerun)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 357)
  • Tuesday Tip of the Week: Don’t Turn a Blind Eye to PBM Management Fees
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 356)
  • Tuesday Tip of the Week: PBM’s are the Only Check on Drug Manufacturers’ Ability to Increase Drug Costs
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 355)
  • Tuesday Tip of the Week: Vertically Integrated Insurers Pivot to Protect Drug Manufacturer Revenue
  • [Free Webinar] The Untold Truth: How Pharmacy Benefit Managers Make Money
April (9)
  • AIDS Healthcare Foundation Taking Tough Stance on PBMs – Pharmacy Benefit Manipulators, Really?
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 363)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 362)
  • Tuesday Tip of the Week: 8 Considerations During Annual PBM Reviews
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 361)
  • Tuesday Tip of the Week: PBMs are Under Attack But Commercial Employers Get Little Help
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 360)
  • Tuesday Tip of the Week: Benefits of Working with a Fiduciary-Model PBM
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 359)
May (12)
  • The Untold Truth: How Pharmacy Benefit Managers Make Money [Free Webinar]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 367)
  • Tip of the Week: Claims Repricings Should Not Be Your Most Important Tool in Evaluating PBM Proposals
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 366)
  • Tip of the Week: Money is good, Information is better [rerun]
  • Large PBM Under Fire for Not Accurately Disclosing the True Cost of its PBM Services
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 365)
  • What’s Worse Than Overpaying for Pharmacy Benefits? Believing You Aren’t.
  • Tuesday Tip of the Week: How Pharmacy Benefit Managers Make Money [Video]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 364)
  • Tuesday Tip of the Week: Dig Deeper into Your Non-Fiduciary PBM’s Financial Shenanigans
  • [Free Webinar] The Untold Truth: How Pharmacy Benefit Managers Make Money
June (10)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 372)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 371)
  • AIDS Healthcare Foundation (AHF) Files Federal Antitrust Lawsuit Against BUCA PBM
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 370)
  • Mississippi AG Files Lawsuit Against Insulin Manufacturers and PBMs over Insulin Pricing Scheme
  • PBM Agrees to Pay a Record $88.3 Million to Settle Ohio Case
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 369)
  • Tuesday Tip of the Week: Specialty Drugs Have Taken Over
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 368)
  • Tip of the Week: Smaller PBMs Grade Higher on Customer Satisfaction
July (11)
  • The Untold Truth: How Pharmacy Benefit Managers Make Money [Free Webinar]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 374)
  • Tip of the Week: Non-Fiduciary PBMs Hedge Against Their Legacy Business Models
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 374)
  • Tip of the Week: The Specialty Drug Pipeline Will Make You Rethink Your Pharmacy Benefits Management Strategy
  • Costco approach could have saved Medicare $2.6 billion in drug spending, analysis shows
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 373)
  • Tip of the Week: Fiduciary Model Pharmacy Benefit Managers (PBM) are a Thing
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 373)
  • Tip of the Week: Pharmaceutical Manufacturers are Light Years Ahead of Commercial and Public Sector Employers, Unions, Health Plans and Health Systems
  • [Free Webinar] The Untold Truth: How Pharmacy Benefit Managers Make Money
August (11)
  • Tip of the Week: How to Eliminate Huge PBM Markups and Reduce Pharmacy Costs by 50%
  • The Untold Truth: How Pharmacy Benefit Managers Make Money [Free Webinar]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 378)
  • Tip of the Week: Drugmakers circumvent health plan sponsor benefit designs, at the switch, to get high-cost brand drugs dispensed
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 377)
  • Ohio awards contract worth billions to the same company it accused of fraud and was later paid $88 million as a result
  • 10 Definitions, Related to Prescription Drug Prices, All Purchasers of PBM Services Should Know
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 376)
  • Tip of the Week: The health plan sponsor hiring a PBM always has the final say on contract terms
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 375)
  • Tip of the Week: Education is the most logical and effective foundation for achieving maximum value in pharmacy benefit management (PBM) services.
September (10)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 382)
  • Tip of the Week: Specialty Drugs Have Taken Over (Rerun)
  • The Untold Truth: How Pharmacy Benefit Managers Make Money [Free Webinar]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 381)
  • Tip of the Week: What is spread pricing, and how does it affect a PBM’s revenues?
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 380)
  • Tip of the Week: How PBMs Help Rein in Drug Spending
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 379)
  • Tip of the Week: A Good Formulary is the Backbone of an Efficient Pharmacy Benefit Program
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 379)
October (13)
  • Just because a drug is approved by the FDA, does not mean it has proof of efficacy [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 386)
  • Three surefire ways to know if your PBM is overcharging you
  • An attorney shares the warning signs of ‘self-serving’ PBMs [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 385)
  • Self-funded employers have a corporate responsibility to understand MAC lists
  • Average Specialty Drug Price Reached $84,442 in 2020, Rising More Than Three Times Faster Than the Prices of Other Goods and Services [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 384)
  • Tip of the Week: How Pharmacy Benefit Managers Make Money [On-Demand Video]
  • Kansas audited its $80 million prescription plan, but it’s still shrouded in mystery [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 383)
  • Tip of the Week: Claims Repricings as the Primary Tool in Evaluating PBM Proposals is Like Buying a Used Car Without Ever Looking Under the Hood [Rerun]
  • How PBM “rebate walls” impact drug spending, patient care and competition [Weekly Roundup]
November (14)
  • Tip of the Week: Don’t Opt-Out of Step Therapy Programs
  • Pharmacy and PBM Leader Deloitte Consulting: Specialty Drugs Rely on Personalization for Optimal Outcomes [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 390)
  • Tip of the Week: How Hospitals and Specialty Pharmacies Get Paid – The 340B Math
  • Medicaid Specialty Drug Trend Finally Surpasses 50% of Pharmacy Spend in Most Recent Pharmacy Trend Report [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 389)
  • Tip of the Week: PBMs that make money through hidden cash flows do so at the expense of client savings and health of members
  • Private insurers pay steep markups for hospital drugs [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 388)
  • Tip of the Week: Three Undervalued PBM Performance Metrics
  • Employer strategies to manage costs for rare diseases [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 387)
  • Tip of the Week: How drugmakers circumvent benefit designs to get high-cost brand drugs dispensed [Rerun]
  • The Untold Truth: How Pharmacy Benefit Managers Make Money [Free Webinar]
December (11)
  • DIR fees from PBMs increased by 91,500% in just 9 years [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 394)
  • The Untold Truth: How Pharmacy Benefit Managers Make Money [Free Webinar]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 393)
  • The Consolidated Appropriations Act (CAA) Introduces Broker Compensation Transparency [Weekly Roundup]
  • Tip of the Week: Think Twice Before Joining a PBM Drug Pricing Coalition (rerun)
  • Understanding the Evolving Business Models and Revenue of Pharmacy Benefit Managers [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 392)
  • Tip of the Week: Think Twice Before Joining a PBM Drug Pricing Coalition
  • Pharmacy Benefit Managers are Outwitting Attempts at Accountability, Tougher Rules [Weekly Roundup]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 391)
2020 (137)
January (12)
  • New Report: Health Plans, PBMs, Employers, and Health Systems Keep $166B in Rebates and Discounts Provided by Drugmakers
  • Physician Practices Must Create a System to Deal with PBM Drug Denials
  • PBM 101 Webinar: How to Slash PBM Service Fees, up to 50%, Without Reducing Benefits or Shifting Costs to Employees
  • Self-Insured Employers Turning to PBMs to Fight Prescription Drug Abuse
  • Infographic: 6 Reasons a Small PBM is as Good as a Big PBM
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 301)
  • U.S. Supreme Court to hear case on States’ Right to Regulate Pharmacy Benefit Managers (PBM)
  • PBM 101 Webinar: How to Slash PBM Service Fees, up to 50%, Without Changing Vendors or Member Benefit Levels
  • Drawing a Line in the Sand California Looks to Contract Directly with Generic Drug Manufacturers
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 300)
  • Chief Economist Writes, “Constraining Pharmacy Benefit Managers Will Not Reduce Drug Prices”
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 299)
February (8)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 303)
  • The ROI on Pharmacy Benefit Management Services; New Study from PCMA
  • Tip of the Week: For your next PBM request for proposal ditch email and paper
  • Value-Based Contracts Slowly Picking Up Steam
  • 3 ways PBMs can team up with employers to save on specialty drugs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 302)
  • Tip of the Week: Don’t Give Up Leverage to PBMs
  • New report alleges that pharmacy benefit managers (PBMs) in Florida are favoring their own affiliated pharmacies
March (13)
  • Tuesday Tip of the Week: Avoid “Bargain Basement” PBM Administration fees
  • PBM Evaluation Process: Is Yours Up to Par?
  • Gross-to-Net Bubble: Brand Drug List Prices Increase 159% and Net Prices 60% from 2007 to 2018
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 306)
  • Tuesday Tip of the Week: Maximize DUM Programs to Manage Costs of Specialty Pharmaceuticals
  • American Pharmacist Association (APhA) Issues Prescription Drug Supply Guidance for Patients and Caregivers
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 305)
  • Tuesday Tip of the Week: Get Your Contract Definitions in Order
  • Non-Fiduciary PBMs Arbitrarily Designate Certain Drugs as “Specialty” Medications
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 304)
  • Large Employer Groups Push Back on Non-Fiduciary PBMs and Win Big!
  • Don’t Miss Webinar: How to Slash PBM Service Fees, up to 50%, Without Reducing Benefits or Shifting Costs to Employees
  • Patient Assistance Programs: A Shield from High Cost or Trampoline for Abuse?
April (12)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 311)
  • Formulary Exclusions are Gaining Popularity
  • Tuesday Tip of the Week: You Should Not Pay a PBM for Your Own Claims Data
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 310)
  • Tuesday Tip of the Week: A PBM Proposing Anything Short of Full Disclosure is a Non-Starter
  • What is the CPBS credential? A podcast with Erin L. Albert, JD, PharmD
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 309)
  • Tuesday Tip of the Week: Who is Watching the Watcher?
  • How the Pharmacy Benefit Management Industry is Reacting to COVID-19
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 308)
  • Tuesday Tip of the Week: One Year PBM Service Agreements are not a Fail-Safe
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 307)
May (11)
  • The Untold Truth: How Pharmacy Benefit Managers Make Money [Free Webinar]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 315)
  • Tuesday Tip of the Week: There are no problems associated with pharmacy costs a PBM consultant can solve that a PBM, if it so chooses, can’t itself solve for self-funded employers
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 314)
  • 6 Pillars of Pharmacy Benefit Plan Design (Rerun)
  • Tuesday Tip of the Week: Price Isn’t the Only Driver of Pharmacy Costs
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 313)
  • Tuesday Tip of the Week: Take DAW 9 Off the Table for Non-Fiduciary PBMs
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 312)
  • Tuesday Tip of the Week: PBMs Must be Fiduciaries
  • The Untold Truth: How Pharmacy Benefit Managers Make Money [Free Webinar]
June (11)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 319)
  • The Untold Truth: How Pharmacy Benefit Managers Make Money [Free Webinar]
  • Tuesday Tip of the Week: 3 Common Places PBM Overcharges Occur
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 318)
  • Specialty Drugs: A Five Pillar Approach to Managing Cost
  • Tuesday Tip of the Week: Spreadsheets as the Primary Tool in Evaluating PBM Proposals is Like Buying a Used Car Without Ever Looking Under the Hood
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 317)
  • Tuesday Tip of the Week: Lead with Transparency or a Non-Fiduciary PBM’s Pricing Analyst will Exploit Your Lack of Sophistication
  • BCBS Insurers in Six States Sue CVS Health Over an Alleged Scheme to Overcharge Them for Generic Drugs
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 316)
  • Tuesday Tip of the Week: Large non-fiduciary PBMs hire members of the Big Four consulting firms to help them identify ways to generate hidden cash flows
July (12)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 324)
  • Tuesday Tip of the Week: Deadlines get deals done
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 323)
  • Tuesday Tip of the Week: Dose Optimization Interventions Yield Significant Specialty Drug Cost Savings
  • Channel Management for Specialty: Challenges with Medical Benefit or Pharmacy Benefit
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 322)
  • Tuesday Tip of the Week: When the carrier, PBM and ASO all share the same parent company you are fully insured
  • Potential Specialty Generic Drugs 2020
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 321)
  • Tip of the Week: Pass-Through and Transparent PBM Business Models are Small Ideas
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 320)
  • Tuesday Tip of the Week: 3 Ways to Prepare for the Inevitable Rise in Pharmacy Benefit Costs
August (11)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 328)
  • Tuesday Tip of the Week: Out-of-pocket caps don’t lead to increased health plan spending or reduced affordability for all enrollees
  • Free Webinar | The Untold Truth: How Pharmacy Benefit Managers Make Money
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 327)
  • Tuesday Tip of the Week: Factor Benefit Design into your PBM Scorecard
  • Pharmacy CEO pleads guilty to $50M reimbursement fraud
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 326)
  • Tuesday Tip of the Week: If I were a plan sponsor here are the seven things I would be asking of PBMs during an RFP
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 325)
  • Free Webinar | The Untold Truth: How Pharmacy Benefit Managers Make Money
  • Tuesday Tip of the Week: Put a Stake in Vampiric PBM Management Fees
September (11)
  • Tuesday Tip of the Week: PBMs can be Fiduciaries
  • Drugmakers Push Back on the Use of Contract Pharmacies by 340B Covered Entities
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 332)
  • Free Webinar | The Untold Truth: How Pharmacy Benefit Managers Make Money
  • Tuesday Tip of the Week: Focus on Lowest Net Cost Drugs
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 331)
  • Tuesday Tip of the Week: Increase out-of-pocket (OOP) spending for specialty drugs
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 330)
  • Tuesday Tip of the Week: When the carrier, PBM and ASO all share the same parent company you are fully insured (Rerun)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 329)
  • Tuesday Tip of the Week: 6 Reasons a Small PBM is as Good as a Big PBM
October (12)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 337)
  • [Webinar] The Untold Truth: How Pharmacy Benefit Managers Make Money
  • Tuesday Tip of the Week: Factor Benefit Design into your PBM Scorecard (Rerun)
  • Bling-Loving Postal Boss Asked to Step Down Over $12,000 Worth of Cartier Watches
  • Dean Foods Carves Out Specialty Pharmacy and Saves Big
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 336)
  • Tip of the Week: Self-insured Employers Must Draw a Line in the Sand between them and Non-fiduciary Pharmacy Benefit Managers
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 335)
  • Tuesday Tip of the Week: Institute new contract terms that do not permit spread pricing
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 334)
  • Tuesday Tip of the Week: 3 Ways Savings Could be Achieved by Improving Pharmacy Benefit Design and Management
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 333)
November (10)
  • Ohio Requesting Bids for Administrator to Oversee its Pharmacy Benefit Program
  • [Free Webinar] The Untold Truth: How Pharmacy Benefit Managers Make Money
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 341)
  • Tuesday Tip of the Week: Non-Fiduciary PBM Rent-Seeking Behavior Eliminates Their Price Advantage
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 340)
  • Tuesday Tip of the Week: 6 Reasons a Small PBM is as Good as a Big PBM [Rerun]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 339)
  • Tuesday Tip of the Week: Specialty Drug Utilization Management Three Things to Know
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 338)
  • Tuesday Tip of the Week: Three Myths about PBM Pricing Every Employer-Sponsored Plan Should Know
December (14)
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 346)
  • Study Finds Non-Fiduciary PBMs are Draining Florida’s Medicaid Funds
  • Internal Email Shows Big Three PBM Was Overcharging – And Knew It
  • [Free Webinar] The Untold Truth: How Pharmacy Benefit Managers Make Money
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 345)
  • Tuesday Tip of the Week: Commercial Employers Pay More Than Public Sector Employers in Spread Pricing
  • Self-Funded Employers: Your Generic Dispense Rate (GDR) Should be 90% or Higher
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 344)
  • Tuesday Tip of the Week: The Untold Truth How Non-Fiduciary PBMs Make Money [Volume 153]
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 343)
  • What is a Copay Accumulator Program and How Does It Work?
  • Tip of the Week: Do’s and Don’ts of PBM RFPs
  • Reference Pricing: “Gross” Invoice Cost vs. AWP for Popular Generic and Brand Prescription Drugs (Volume 342)
  • Tuesday Tip of the Week: 3 Ways for Employers and HR Pros to Know If They Have Selected the Right Insurance Broker for Pharmacy Benefits
2019 (141)
January (12)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 256)
  • Big Pharma is Slow to Allow Health Outcomes to Dictate Pricing — At Least For Now
  • Outcomes-Based Contracting for Prescription Drugs is Set to Accelerate
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 255)
  • Access to Drug Cost Data Before Leaving the Doctor’s Office
  • Employers are Sticking it to Employees, with Rebates, for a Couple of Dollars in Savings
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 254)
  • CVS makes dubious case for rebates’ impact on drug prices
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 253)
  • Turns out CVS’s “New” Guaranteed Net Cost Pricing Model is More of the Same – That is Bait and Switch
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 252)
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
February (7)
  • How to Save $1.6 Million Bucks: 5 Tips for Cutting Specialty Pharmacy Costs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 259)
  • How Self-Funded Employers Leave Employees Holding the Bag: The Copay Clawback Phenomenon:
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 258)
  • A Closer Look into the Popular Pricing Benchmark: Average Wholesale Price (AWP)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 257)
  • Ohio’s State Auditor Just Released its Full Report on PBM Transparency and You Won’t Believe Your Eyes
March (13)
  • Electronic Prior Authorizations (ePA) Save Plan Sponsors Time and Money
  • Understanding the Complexity of DIR Fees
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 263)
  • Robbing Peter to Pay Paul: Co-Pay Accumulator Programs Could be Doing More Harm Than Good
  • Smaller independent pharmacies consistently offer cheaper options than chain pharmacies
  • Don’t look now but things are getting even more complicated: Point-of-sale discounts (rebates) to consumers as part of employer-sponsored plan design
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 262)
  • A Lack of Competition Leads to Brand Drug Price Increases
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 261)
  • Uncovering Hidden Specialty Drug Spend Outside of the Pharmacy Benefit
  • Eli Lilly and Company to Offer Generic Insulin at 50% Off Brand Name Humalog
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 260)
April (10)
  • Copay Accumulator Programs Now Allowed by CMS to Encourage Switch to Generic Drugs
  • Ohio’s Attorney General Calls for PBMs to Operate as Fiduciaries
  • Are specialty drug pricing spreads the new money pit vis-a-vis rebates?
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 266)
  • Short fills eliminate medication waste and reduces costs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 265)
  • Cross-walk HCPCS codes to NDC codes for granular medical benefit drug claim (MBDC) information
  • Bureau of Securities Releases Rule to Impose Fiduciary Duty on Brokers
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 264)
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
May (11)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 270)
  • Good Options To Help Self-Insured Employers Improve PBM Contracting Efficiency
  • Kentucky Report: “Opening the Black Box” Reveals Non-Fiduciary PBMs Took Home $123 Million From Spread Pricing
  • Sweeping Health Care Legislation Proposal Calls for Disclosure of Perks and Fees Paid to Health Benefits Brokers
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 269)
  • Elimination of PBM Gag Clauses Allow Independent Pharmacies to Save Patients Money on Prescription Drugs
  • Top 7 Reasons the PBM Industry is Ripe for Disruption
  • Here’s one reason why prescription drug prices are so high: the fix is in!
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 268)
  • “The Big Payback” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 267)
June (11)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 273)
  • Help is on the way: Federal lawsuit accuses generic drug makers of using “code” to fix price increases
  • AARP Report: Specialty Drug Prices Soar to Nearly $79,000 per Year
  • Another opaque PBM contract bites the dust
  • Could proposed rebate rule be a once-in-a-generation opportunity to reset our system to work better?
  • Ohio Cancels Bad PBM Contracts and Quickly Gets a Better Deal
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 272)
  • Massachusetts Health Policy Commission report: Non-fiduciary PBMs are driving up health care costs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 271)
  • “The Big Payback” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • CVS’s Push Into Your Doctor’s Office
July (13)
  • Trump Administration ‘Opens Pathway’ on Drug Imports From Canada
  • Impact of a Co-pay Accumulator Adjustment Program on Specialty Drug Adherence
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 277)
  • Flow of the Specialty Drug Dollar: A Business Process Model with Notation
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 276)
  • DIR fees in Medicare Part D grew by 45,000% between 2010 and 2017
  • The White House Yanks Proposed Drug Rebate Overhaul
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 275)
  • Largest pharmacy benefits manager in the U.S. accused of costing the New York City Transit Authority tens of millions of dollars
  • Court Declines to Enforce Indemnification Provision Against Negligent Pharmacy Benefits Manager
  • UnitedHealth’s PBM unit, Optum, tops $100 billion in revenues for the first time
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 274)
  • State’s attempt to curb pharmacy benefit manager service fees mostly futile
August (13)
  • Pension Funds Sue Insulin Manufacturer for $1.75 Billion over Alleged Collusion
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 282)
  • PBM 101 Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Targeted Medication Reviews (TMRs) Critical Success Factor for Medication Therapy Management
  • Op-ed: PBMs are Driving Up Costs and Lowering Quality Care in America
  • Self-funded employers spend 40% of costs on less than 1% of prescriptions
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 281)
  • How an Stand-alone PBM Uses Patient Engagement to Improve Cost and Patient Outcomes
  • Medicare and its beneficiaries could have saved an estimated $17.7 billion if older generics were prescribed, study finds
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 280)
  • Plan Sponsors Laser Focused on High-Cost Claims
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 279)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 278)
September (12)
  • Milton Friedman’s Shareholder Theory Is Wrong Afterall
  • How to Assess the Value of Cell and Gene Therapies: ICER’s Founder
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 286)
  • Can Formulary Management Bring Specialty Drug Spend Back Down to Earth?
  • AARP Rx Price Watch Report Shows Prescription Drug Prices Increase by Double the Rate of Inflation
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 285)
  • Special Report: Reducing Wasteful Spending in Employers’ Pharmacy Benefit Plans
  • Oncologists Getting 6% of Drug Price Is ‘Financial Conflict’
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 284)
  • Site of Care Management: Administering specialty drugs outside hospitals could save $4 billion
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 283)
  • Opinion Editorial: A reckoning is coming for non-fiduciary PBMs
October (10)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 290)
  • New York Firefighters Association Cracks Down on Non-Fiduciary Pharmacy Benefit Managers
  • Prime Therapeutics Study: Number of ‘Drug Super Spenders’ Grew 63% In 3 Years
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 289)
  • Wasteful Spending in Healthcare Estimated at $760B to $935B
  • Michigan wants to save $40 million by cutting non-fiduciary PBMs out of Medicaid
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 288)
  • Courts Look Closely at the Contractual Relationship Between Plan Sponsor and PBM
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 287)
  • New prescription drug pricing system reins in non-fiduciary pharmacy benefit managers
November (13)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 295)
  • OptumRx overcharged Ohio BWC by millions, Attorney General says
  • A Prominent Attorney and Advocate for PBM Transparency Says State Medicaid Plan Hemorrhaging Money
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 294)
  • American College of Physicians Position Paper: Recommendations for PBMs to Stem the Escalating Costs of Prescription Drugs
  • California is Carving Out Pharmacy Benefits
  • AARP has released a new Rx Price Watch report
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 293)
  • Holy cow! Diplomat Pharmacy is a shell of its former self
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 292)
  • Benefits Alert: Chronological Timeline of Prescription Drug Copay Accumulator Programs
  • Infusing Radical Transparency into PBM Contracts
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 291)
December (16)
  • Reducing Wasteful Spending in Employers’ Pharmacy Benefit Plans; Special Report (Rerun)
  • Wasteful Spending: Check out the price tags on combination prescription drugs
  • BCBS of Tennessee will stop reimbursing providers for certain specialty drugs typically administered in a doctor’s office or hospital setting
  • Feds Finally Release Proposed Drug Importation Policies
  • U.S. Pharmacy Reimbursement and Distribution System (Rerun)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 298)
  • Doctors Prescribe More of a Drug If They Receive Money from a Pharma Company Tied to It
  • Express Scripts to handle drug rebate negotiations, on the pharmacy benefit, for Prime Therapeutics
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 297)
  • Researchers find surgery for blocked arteries is often unnecessary
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 296)
  • Geesh! UnitedHealth’s Optum paying $300 million for Diplomat specialty pharmacy
  • Specialty Generic and Biosimilar Drug Pipeline Update
  • PBM 101 Webinar: How to Slash PBM Service Fees, up to 50%, Without Reducing Benefits or Shifting Costs to Employees
  • Generic Drug Pipeline Update
  • In 2020, Optum To Provide More Than 50% Of UnitedHealth’s Total Company Earnings
2018 (142)
January (13)
  • Lawmakers Seek Transparency in 340B Program
  • FDA Approved Record-Breaking Number of Generics in 2017
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 203)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 202)
  • Why pharmaceutical companies, under attack for drug prices, started an industry war
  • Health care deals could make you healthier but may not save you money
  • Maryland Group Challenges Pharmacist Gag Clause on Drug Costs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 201)
  • The Death of Objectivity
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 200)
  • Drug prices rise as big pharma profit soars
  • More transparency on generic drug acquisition cost data could save $4 billion
February (11)
  • Hidden Profits In the Prescription Drug Supply Chain
  • 7 techniques to blunt specialty drug costs hardly any self-insured employer is doing right or at all
  • What might the Amazon, Berkshire and JP Morgan health care joint venture actually do?
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 207)
  • Prescription Drug Coupons: A One-Size-Fits-All Policy Approach Doesn’t Fit The Evidence
  • Biosimilars Are Not “Generic” Versions Of Expensive Biologic Medicines
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 206)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 205)
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Top 8 Specialty Drug Categories Driving Spending in 2018
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 204)
March (14)
  • What’s your decision flow process?
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 212)
  • Clinical Reviews | An underused way to save big on pharmacy benefits
  • U.S. spending on drugs will grow faster than on other health-care services over the next decade
  • 10 Steps to Improving Your Company’s Pharmacy Benefit Management Results
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 211)
  • Fiduciary PBMs emerge as response to consolidation of Rx dispensing, concern over conficts of interest and need for deeper clinical expertise
  • Generic Hepatitis C Drugs Begin to Emerge
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 210)
  • 6 Pillars of Pharmacy Benefit Plan Design
  • A costly PBM trick: set lower copays for expensive brand-name drugs than for generics
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 209)
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 208)
April (13)
  • Therapeutic Interchange: How It Could Affect Patients and Plan Sponsors
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 216)
  • The role of PBMs in the drug supply chain — and why it matters to employers
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 215)
  • Amazon About-Face On Drug Sales Not Surprising To Walgreens And CVS
  • The Price of Non-Optimized Medication Therapy
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 214)
  • Two Generic Medications Become One Cash Cow Drug
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • When left to their own accord, non-fiduciary PBMs will act in their own self-interest
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 213)
  • Newer Specialty Drugs Require Payers to Revise Coverage Strategies
  • Standing pat can’t be a long-term strategy for self-insured employers
May (12)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 221)
  • Amgen, AbbVie ‘ahead of the crowd’ in fighting payers’ latest assault on copay coupons
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 220)
  • Trump’s Drug Blueprint Could Alter PBM Contracting
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 219)
  • Appellate court kills Optum’s $6.7B pharmacy benefits management contract; orders rebid
  • From $14000 to $8000 Overnight with Almost No Restrictions; Cholesterol Drug has Potential to Break Self-Insured Employers’ Bank
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 218)
  • Longtime chief of pharmacy benefit manager trade group to step down
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 217)
  • ESI Reachs Deal on Struggling Cholesterol Drug with a List Price Over $8000
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
June (11)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 225)
  • What is a fair share? Pharmacy middlemen made $223.7M from Ohio Medicaid
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 224)
  • Dereliction of Fiduciary Duties by CFOs and HR Execs Triggering Department of Labor Investigations
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 223)
  • 3 strategies for reducing pharmacy costs
  • State Rx law cut down on appeal; benefits manager group prevails in federal panel ruling
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 222)
  • Mergers between health insurers and pharmacy benefit managers could be bad for your health
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Why CVS Loves ObamaCare
July (12)
  • FDA Biosimilar Plan Offers Employers Saving Strategy Solution
  • Meet the Rebate, the New Villain of High Drug Prices
  • Million-dollar+ medical claims increase 87 percent from 2014-2017: Sun Life report
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 229)
  • The Bezos-Buffett-Dimon health care venture: Eliminate the middlemen
  • Department of Health and Human Services (HHS) Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 228)
  • Amazon’s PillPack deal puts PBMs, advisers on notice
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 227)
  • IFEBP provides tips on managing specialty drugs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 226)
  • Clawbacks: Settling the score with non-fiduciary pharmacy benefit managers
August (13)
  • BCBS of Tennessee: Prescription Drugs Have Become the Single Leading Cost Driver
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 234)
  • Is consolidation in health care good for employers?
  • Three Ways to Avoid Bankrupting Costs for Medical Spend J Code Drugs
  • Large PBM is staking out million-dollar gene therapies
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 233)
  • Auditor’s Report: Pharmacy Benefit Managers Take Fees of 31% on Generic Drugs Worth $208M in One-Year Period
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 232)
  • Ohio Medicaid pulls the plug on contracts with two big PBMs over ‘spread’ pricing
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 231)
  • Secret discounts paid by drugmakers to pharmacy benefit managers are going away so now what?
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 230)
September (12)
  • Abolishing Drug Rebates May Push Consumer Drug Costs Higher
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 238)
  • Gilead to launch generic versions of its hepatitis drugs
  • Fiduciary rule revival: Should it apply to pharmacy benefits managers?
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 237)
  • Why third-party payers are gobbling up PBMs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 236)
  • The Marriott Rewards Program and Non-Fiduciary PBMs have a lot in common
  • The Secret Drug Pricing System Middlemen Use to Rake in Millions
  • Health Plan with 495,000 Covered Lives Says Prescription Medications Account For One in Four Dollars Spent
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 235)
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
October (10)
  • Most employers (60%) aren’t tracking wasteful healthcare spending
  • PepsiCo and ExxonMobil Team Up with Express Scripts to Create Pharmacy Benefit Design for Radical Transparency and Greater Performance Accountability
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 242)
  • UnitedHealth has bought another billion-dollar pharmacy business
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 241)
  • Another big PBM has confirmed it’s primary objective isn’t to contain prescription drug costs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 240)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 239)
  • A Tough Negotiator Proves Employers Can Bargain Down Health Care Prices
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
November (11)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 247)
  • 4 Key Factors Employers Must Consider When Evaluating Specialty Pharmacy Performance
  • State Settles $500k Dispute with a Big Three Pharmacy Benefits Manager
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 246)
  • Express Scripts announces “new” formulary that favors lower-cost generics
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 245)
  • Achievement is Significant But Comes with a Huge Price Tag: New Regulation Requires Regulatory Oversight of Pharmacy Benefit Managers (“PBMs”)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 244)
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Unless Your Company Has Money to Burn Don’t Ignore These 7 PBM Contract Pitfalls
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 243)
December (10)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 251)
  • Are Biosimilars the Future of Specialty Pharmacy?
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 250)
  • Pennsylvania’s Auditor General Demands PBM Contracting Transparency
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 249)
  • Ninety-Two Percent of Self-Insured Companies Lack a Formalized Pharmacy Benefits Management Process
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 248)
  • CVS Health launches “New” Guaranteed Net Cost Pricing Model
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Union takes to task pharmaceutical manufacturer on a $6,000,000 per year specialty drug
2017 (141)
January (12)
  • Pharmaceutical Companies Not Seeing Majority of Drug Revenue
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 152
  • Diplomat Pharmacy, Inc. has published a new report on the state of specialty pharmaceuticals
  • Secret rebates erode drugmaker revenue, industry study says
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 151
  • Plan Sponsors Zero In on Specialty Pharmacy Costs in 2017 Benefits
  • Pharmacy Benefit Manager disclosure law preempted by federal benefits law, the U.S. Court of Appeals for the Eighth Circuit ruled
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 150
  • The Future of Employer-Sponsored Coverage
  • “Don’t Miss” webinar Tuesday January 10 at 2PM ET
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 149
  • Pharmacy benefit managers could be in legislative crosshairs
February (11)
  • Pharmacists sworn to secrecy as PBMs force customers to overpay for drugs
  • How to Rein In the Soaring Costs of Specialty Drugs
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 156
  • Key to rebate cost savings, define which drugs are actually eligible for rebates
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 155
  • Employers Take Extra Steps to Curb Specialty Drug Costs
  • Prescription Drug Pipeline: Drugmaker to Patient Explained [Infographic]
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 154
  • Six Takeaways: How are prescription drug prices set?
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 153
March (14)
  • Out-of-pocket costs based on drug list prices; a hidden fee
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 160)
  • How do insurance companies decide what medicines to pay for and when to pay for them?
  • Understanding the Villain of Big Pharma: Traditional Pharmacy Benefit Managers
  • Pharmacy Benefit Manager Back-end Fees Rise $13 Billion in 3 Years
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 159)
  • The “TROUBLES” with Pharmacy Benefit Managers
  • What Outcomes-Based Contracting Means For Drug Development & Drug Pricing
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 158)
  • Drugmaker Says Pharmacy Benefit Managers Keep Prices High
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 157
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Drug Costs Too High? Fire the Middleman
  • Fancy Pill-Reminder Box Isn’t Helping Patients Remember Anything
April (12)
  • How do manufacturer rebates impact drug prices?
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 164)
  • Anthem, Express Scripts largest customer, will not renew its contract with the pharmacy benefit manager
  • Second biosimilar to Remicade approved by the FDA
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 163)
  • What’s your PBM IQ? Take our quiz to find out.
  • What to do About Rising Health Care Costs?
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 162)
  • New Solutions for Curbing Runaway Drug Costs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 161)
  • Prescription Drugs Account for 22% of Payer Premium Spending
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
May (11)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 169)
  • Behind the War Between Health Insurers and Pharmacy Benefit Managers
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 168)
  • Explained: Why your PBM isn’t pass-through
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 167)
  • A Whistle-Blower Tells of Health Insurers Bilking Medicare
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 166)
  • Inside the ‘Scorpion Room’ Where Drug Price Secrets Are Guarded
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 165)
  • California Advances PBM “Transparency” Law
June (10)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 173)
  • What Effect Will Anthem-Express Scripts Fallout Have on Industry?
  • [Video] Pharmacy Benefits Manager Explained
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 172)
  • How ‘price-cutting’ middlemen are making crucial drugs vastly more expensive
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 171)
  • In Washington, everyone is for lower drug prices, but only in theory
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 170)
  • Loaded Dice: How Non-Fiduciary PBMs are Winning the Cash and Rebate Game
July (12)
  • Unaccountable Benefit Managers: How PBMs Put Profits Over Patients
  • Pharmaceutical manufacturer drug coupons days may be numbered
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 177)
  • Large group employers are currently struggling to afford specialty drugs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 176)
  • This story should terrify the employee benefits and PBM industries
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 175)
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Kaleo fires back at Express Scripts, claiming it’s owed at least $5.3M
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 174)
  • Learned Helplessness: The Biggest Reason Non-Fiduciary PBMs Getaway with Overbilling
  • Maryland Is First to Ban “Price Gouging” on Generic Drugs, but Other State and Federal Initiatives May Soon Follow
August (13)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 182)
  • Implementing Reference Pricing Led to Changes in Drug Selection, Lower Spending
  • Here’s how a non-fiduciary PBM controls information and pricing
  • Take the Generic, Patients Are Told. Until They Are Not.
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 181)
  • New Website Launches to Educate About DIR Fees
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 180)
  • Express Scripts’ profit grows despite dwindling revenue from Anthem
  • Lawsuit against CVS could blow up what you thought you knew about drug prices
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 179)
  • What’s your PBM IQ? Test your pharmacy benefits competency.
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 178)
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
September (12)
  • Impact of Biosimilar Approvals on the Pharmaceutical Market
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 186)
  • Cost Containment Strategies and Vendor Contracting Employers’ Top Health Plan Concerns
  • Pfizer Files Lawsuit Against J&J, Claiming Anticompetitive Practices
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 185)
  • New Hep C Pricing Model: A Game Changer for Self-Funded Employers
  • Insurers cutting back on drug coupons amid concerns over consumer costs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 184)
  • PBMs Look to the Future
  • PBM’s and More: In A World of Cost Plus, Is Transparency a Dirty Word?
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 183)
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
October (12)
  • Only 30% of Employers Get Pharmacy Benefit Manager Contracts
  • Taking a More Active Role: The Main Ingredient for Controlling Prescription Drug Costs
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 190)
  • The Top 200 Prescription and Non-Prescription Drugs, by volume, of 2017
  • Anthem, CVS Health sign 5-year deal for a new PBM dealing a blow to Express Scripts
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 189)
  • Formulary Management: Don’t Allow the Fox to Guard the Henhouse
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 188)
  • The Spread and I’m not talking about Miracle Whip
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 187)
  • Hospital Impact—Pharmacy benefit managers are a lot like car dealers
November (12)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 195)
  • Non-Fiduciary Pharmacy Benefit Managers: The Sopranos of the Pharmaceutical Industry
  • Specialty Drugs Paid Under Medical Benefit Circumvent Cost Control Measures
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 194)
  • OptumRx is now caught up in the court battle between Anthem and Express Scripts
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 193)
  • Reverse Auction Helps New Jersey Save $1.6 Billion on Prescription Drugs
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 192)
  • Controversy heats up over pharmacy benefit manager DIR fees
  • PBM Service Fees: The One Topic Which Rarely Comes Up During Contract Negotiations
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 191)
December (10)
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 199)
  • CVS-Aetna merger is a robber baron’s dream come true
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 198)
  • CVS-Aetna Merger Will Influence Employers’ Benefits Decisions: Aon
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 197)
  • Consultants warn ‘change or get out of the way’ next year
  • Prescription Drugs May Cost More With Insurance Than Without It
  • Reference Pricing: “Gross” Invoice Cost for Popular Generic and Brand Prescription Drugs (Volume 196)
  • “Don’t Miss” Webinar: How to Slash PBM Service Costs, up to 50%, Without Changing Vendors or Benefit Levels
  • CVS buying Aetna in deal valued at $69 billion
2016 (132)
January (11)
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 103)
  • Employers Turn to Deductibles, Out-of-Pocket (OOP) Limits to Manage Prescription Drug Costs
  • Despite Obamacare, prescription drug discount cards are still relevant
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 102)
  • With coupon programs, drug industry hides ballooning costs of expensive new medicines
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 101)
  • Anthem seeks $3B more in drug savings from Express Scripts
  • Prescription Drug Launch Forecast – 2016
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 100)
  • How Pfizer set the cost of its new drug at $9,850 a month
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 99)
February (11)
  • Employers Take Aim to Curb High Cost of Pharmacy Benefits
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 107)
  • Economists Debate: Fight With or Adapt to Rising Drug Prices?
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 106)
  • PBM Tools Play Key Role in Managing Specialty Drug Costs
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 105)
  • Hospitals launch specialty pharmacies to curb drug costs
  • PBMs Provide Policy Solutions to Reduce Rx Costs, Increase Competition
  • NCPA to Congress: Scrutinize PBM Corporations as Part of Drug Cost Review
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 104)
  • New York requires PBM contracts to include dispute resolution provisions
March (14)
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 112)
  • Stemming the Escalating Cost of Prescription Drugs: A Position Paper of the American College of Physicians
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 111)
  • Unbundling the Secrets of Managing Drug Costs in the Era of Value-Based Care
  • Employers scramble to keep lid on climbing specialty drug costs
  • More Large Employers Self-funding Pharmacy Benefit Plans
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 110)
  • Surprise proposal: Medicare wants to jump on the value-based prescription drug pricing bandwagon
  • For Pharmacy Benefits, Is Greater Choice Always Better?
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 109)
  • Employers testing new ways to rein in specialty drug costs
  • Drug distribution becomes a weapon to block competition
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 108)
  • Employers Doubling Down on Pharmacy Costs
April (11)
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 116)
  • Express Scripts generates top-line revenue of $76.63 per claim!
  • Game of Thrones: Express Scripts Holding Company Countersues Anthem
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 115)
  • Shining a Light on the Dark Practice of Rx Price Gouging
  • Center for Medicare and Medicaid Services New Plan to Curb Medicare Prescription Drug Price Inflation
  • National Drug Spend | $310B in 2015 and projected to double by 2020
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 114)
  • Recent Trends in Prescription Drug Costs
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 113)
  • OptumRx and Walgreens to partner on 90-day prescriptions
May (10)
  • Specialty Pharmacy Spending Continues to Grow
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 120)
  • 1 Number From CVS Health That Blew Me Away
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 119)
  • High cost or high value? Specialty pharmaceuticals add to employers’ health care costs
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 118)
  • U.S. Investigates Drugmaker Contracts With Pharmacy Benefit Managers
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 117)
  • [VIDEO] Why Your PBM’s Business Model Matters
  • High-cost specialty drugs; predictions for the future
June (12)
  • Express Scripts, Anthem Face ERISA Lawsuit Over Drug Pricing
  • Workplaces Fight Skyrocketing Prescription Drug Costs
  • Review vs Audit: A Comparison of Services Performed by Pharmacy Benefit Management Consultants
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 124)
  • The 7 Habits Of Highly Effective Benefits Professionals
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 123)
  • Drug companies fight generics with coupons
  • Pharmacy Benefit Managers offer a commodity. Do not treat them as differentiated services.
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 122)
  • UHC administered self-insured health plan, AT&T, sued in federal court for embezzlement, self-dealing in medical claims overpayment offset dispute
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 121)
  • Concerns Persist about the 340B Discount Program
July (10)
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 128)
  • Employers falling short on managing healthcare costs
  • Reference Pricing: “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 127)
  • Anthem, Express Scripts dispute comes down to pricing…as should all PBM service agreements
  • Back-billing: an opaque process which significantly increases plan sponsors’ pharmacy costs
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 126)
  • 10 Essential Facts About Medicare and Prescription Drug Spending
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 125)
  • Hold middlemen’s feet to the fire to cauterize specialty drug spending
  • Decoding Big Pharma’s Secret Drug Pricing Practices
August (12)
  • Reference Pricing: Actual Acquisition Cost (AAC) for Top Selling Generic and Brand Prescription Drugs – Volume 132
  • Hand caught in cookie jar, United Healthcare changing drug overpayment program
  • New Report Identifies Most Expensive Specialty Drugs
  • Who is getting rich from the price of prescription drugs?
  • Reference Pricing: Invoice Cost (Gross) for Top Selling Generic and Brand Prescription Drugs – Volume 131
  • Solutions for Reducing Patient Cost Sharing for Prescription Medications
  • Should drug prices be tied to patient outcomes?
  • Reference Pricing: Invoice Cost (Gross) for Top Selling Generic and Brand Prescription Drugs – Volume 130
  • In-Office Dispensing: A Better Value?
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 129)
  • Big companies form an alliance to find ways to reduce pharmacy costs
  • A Path Forward for Lowering Prescription Drug Prices
September (11)
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 137
  • Can ‘Pay for Performance’ Control High Drug Prices?
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 136
  • [Video] PBMs | Bigger Doesn’t Mean Better
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 135
  • Chicken Soup for the Self-Funded Employer: Foolproof PBM Contracts
  • One slide from my “don’t miss” webinar Tuesday September 13 at 3:00 PM ET
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 134
  • [Podcast] Rx Drugs and the U.S. Health System – A Conversation About Drug Prices
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 133
  • The co-pay card debate simmers, as payers push back
October (10)
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 141
  • Survey supports transparency of drug pricing by pharmacy benefit managers
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 140
  • Employers Overpay 10-50% on Health Benefits: Time for a Second Opinion
  • Pipeline to Profits: How Drug Middlemen Make Money
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 139
  • Insulin costs are way up, but drugmakers say PBMs are collecting the loot
  • One slide from my “don’t miss” webinar Tuesday October 11 at 3:30 PM ET
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 138
  • Drugmakers Point Finger at Middlemen for Rising Drug Prices
November (9)
  • Side Effects: The new role of PBMs [VIDEO]
  • A Sick Calculation About Prescription Drugs
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 144
  • Minnesota Department of Health finds drugs given in medical settings are big drivers of costs
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 143
  • Claims Analysis: Negotiated Pricing Between Preferred and Non-Preferred Retail Pharmacies
  • PAs (prior authorization) work, if done right
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 142
  • [Podcast] Rx Drugs and the U.S. Health System – A Conversation about Election-Cycle Proposals for Lowering Costs
December (11)
  • High-Priced Drugs: Estimates of Annual Per-Patient Expenditures for 150 Specialty Medications [Report]
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 148
  • Top pharmacy challenges of 2017
  • Pharmacy benefits: Super-sized, minimized or right-sized?
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 147
  • Pay-for-performance drug pricing: drugmakers asked to eat costs when products don’t deliver
  • “Don’t Miss” webinar Tuesday December 13 at 2PM ET
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 146
  • Drugmaker sheds light on path of rebate dollars
  • Integrating pharmacy benefit, medical benefit cuts costs
  • “Gross” Invoice Cost for Top Selling Generic and Brand Prescription Drugs – Volume 145
2015 (101)
January (8)
  • Top 10 trends shaping the health industry in 2015
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Drug Distributors Build Strength In An Era Of Change
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Prevent prescription drug monopolies
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Specialty Drug Approvals: Review 2014 and a Forecast for 2015
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
February (9)
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Mild to aggressive; remedies for reducing prescription drug prices
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Specialty Pharmacy: The Top 10 Trends Payers Should Be Following
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Generic drug price hikes hit pharmacists and payers
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • [Infographic] The Cost of Innovation: How Specialty Drugs Impact Healthcare
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
March (8)
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Should Specialty Drugs Be Shifted From Medical to Pharmacy Benefit?
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • When It Comes to New Drugs, If Providers and Payers Snooze, They Lose
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • [Video] The Challenge of Getting Specialty Drugs from Manufacturer to Patient
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • The Makings of a Good Drug Formulary
April (8)
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Proof: The People PBMs Hire to Hide Cash Flow From Employers
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • 6 ways to lower healthcare spend vis-à-vis specialty pharmacy
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • 5 Keys to Managing Your Company’s Pharmacy Benefit in a Dynamic Health Care Marketplace
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • The malevolence of all health care sectors
May (9)
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • New Push Ties Cost of Drugs to How Well They Work
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Why do pharmacy benefit managers (PBMs) overcharge their clients?
  • Price vs Patient Access: Specialty’s Unsettling Conundrum
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Rare Look: A Detailed Analysis of an Existing Client’s Old Contract with a Legacy Pharmacy Benefits Manager
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • The Rise of Speciality Drugs: Is Your Health Plan Prepared?
June (8)
  • Reference Pricing: “Net” Ingredient Cost for Top Selling Generic and Brand Prescription Drugs
  • 125 Things to Know About the ‘Big 5’ Insurers
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • The Curious Incident of the $44,000 Prescription
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • OIG Highlights Anti-Kickback Risks of Drug Co-payment Coupons
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Pharmacy Discount Cards: Scam or Savings?
July (10)
  • Reference Pricing: “Net” Ingredient Cost for Top Selling Generic and Brand Prescription Drugs
  • Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise
  • Reference Pricing: “Net” Ingredient Cost for Top Selling Generic and Brand Prescription Drugs
  • Emerging Trends in the Specialty Drug Market
  • Reference Pricing: “Net” Ingredient Cost for Top Selling Generic and Brand Prescription Drugs
  • Will Specialty Oncology Products Follow the Sovaldi Way?
  • Reference Pricing: “Net” Ingredient Cost for Top Selling Generic and Brand Prescription Drugs
  • Controlling Pharmacy Costs
  • Reference Pricing: “Net” Ingredient Cost for Top Selling Generic and Brand Prescription Drugs
  • Time to Blow Up Your PBM Strategy — Here’s How
August (8)
  • Reference Pricing: “Net” Ingredient Cost for Top Selling Generic and Brand Prescription Drugs (Volume 82)
  • Specialty Drug Costs Prompt Employers to Tighten Their Belts
  • Reference Pricing: “Net” Ingredient Cost for Top Selling Generic and Brand Prescription Drugs (Volume 81)
  • Large Employers Look To Tighten Control Of Costs For Expensive Drugs
  • Reference Pricing: “Net” Ingredient Cost for Top Selling Generic and Brand Prescription Drugs (Volume 80)
  • Pharmacy Podcast Show – The Fiduciary PBM
  • Reference Pricing: “Net” Ingredient Cost for Top Selling Generic and Brand Prescription Drugs (Volume 79)
  • Shocker: CVS Allegedly Overcharged Employers (Payers) for Prescription Drugs
September (9)
  • How the national drug debate is changing the pharmacy benefit business
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 86)
  • Can payers and plan sponsors be held responsible for questionable pharmacy benefit manager practices?
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 85)
  • Studies try to help pill regimen adherence
  • Reference Pricing: “Net” Ingredient Cost for Top Selling Generic and Brand Prescription Drugs (Volume 84)
  • Rising Cost Of Drugs: Where Do We Go From Here?
  • Reference Pricing: “Net” Ingredient Cost for Top Selling Generic and Brand Prescription Drugs (Volume 83)
  • State In Legal Battle Over Prescription Drug Benefits
October (8)
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 91)
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 90)
  • Some multi-source (generic) prescription drugs cost roughly as much as their brand name rivals: Here’s why
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 89)
  • Building the In-house Pharmacy Benefit: Three considerations for the health system as plan sponsor
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 88)
  • For Prescription Drug Makers, Price Increases Drive Revenue
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 87)
November (9)
  • Specialty drugs in the pipeline: 4 heavily impacted diseases
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 95)
  • Amgen Agrees to Pay-for-Performance Deal With Harvard Pilgrim Health Care Plan
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 94)
  • Payers: Forget specialty drug costs—generic prices are crushing our budgets, too
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 93)
  • PBMs wed with promise of savings, but reduction in choice may hurt employers
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 92)
  • How self-funded employers can tackle double-digit prescription drug cost increases
December (7)
  • Drug Prices Are Too Damn High. Here’s How to Fix Them
  • Employers Battle Drug Costs
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 98)
  • Who Has the Power to Cut Drug Prices? Employers.
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 97)
  • Prescription Drug Spending For State Employees Runs Wild, Despite Cost-Saving Efforts
  • Reference Pricing: “Net” Invoice Cost for Top Selling Generic and Brand Prescription Drugs (Volume 96)
2014 (80)
January (7)
  • 2014 Launch Forecast for Generic Prescription Drugs
  • Reference Pricing: Pharmacy Invoice Cost for Top Selling Generic and Brand Prescription Drugs
  • The Pharmacy Benefits Manager RFP; 7 Contract Tips for a Cost Efficient Drug Benefit Design
  • Pharmacy Cost [invoice] for Top Selling Brand and Generic Prescription Drugs
  • PBMs and generic drugs: Is the good news ending?
  • Pharmacy Invoice Prices (Actual) for Top Selling Generic and Brand Prescription Drugs
  • Mail order drug systems more cost effective than brick-n-mortar pharmacies
February (7)
  • CMS Proposed Rules on Medicare Part D
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Limited Pharmacy Networks are Changing Employer Sponsored Prescription Drug Benefits
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Pharmacy Network Reimbursement Rates
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
March (7)
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Eight Reasons Employers Overpay For PBM Services
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • What is the True Cost of PBM Services?
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Do drug benefit managers reduce health costs?
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
April (6)
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Early Pharmacy Claims Data from Exchange Enrollees Indicate High Usage
  • [Video]: Prices Soaring for Specialty Drugs
  • Experts warn employers to prepare for high costs of specialty drugs
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Lawmakers seek more pricing info from PBMs
May (6)
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Video: Specialty Drug Pricing Discussion on Nightly Business Report
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Plan Sponsors’ Satisfaction With PBMs Remains Relatively Unchanged
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • IMS Report: Specialty Medications Drive Prescription Drug Spending Increase
June (7)
  • 2014 Generic Prescription Drug Launch Forecast
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Average Wholesale Price (AWP) for Twelve of the Most Expensive Specialty Drugs
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Industry Consolidation Is Impacting PBM Customer Service
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • The Insurance Industry is Picking a Fight with Pharmaceutical Companies Over the Rising Cost of Specialty Drugs
July (8)
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Reality Check: US Consumer Drug Costs Climb Ever Higher
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Restrictive formularies: A path to more affordable drug prices
  • Specialty Drugs: A Proactive Approach to Sustained Cost Containment
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • 2015 Generic Prescription Drug Launch Forecast
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
August (6)
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Prescription drug tiers can’t handle all budget woes, study shows
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • 2014 Generic Prescription Drug Launch Forecast [UPDATED]
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Insurance Industry, Consumers Join Forces to Fight High Prices of Specialty Drugs
September (8)
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • States step in to regulate drug copays
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Drug prices soar as Big Pharma targets discount program
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • 10 Things To Know About Specialty Drug Spending
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • 2015 Generic Prescription Drug Launch Forecast [UPDATED]
October (9)
  • Friction Between Health Plans, Pharma Grows Over Specialty Drugs
  • Pharmacy Carve-Out: 7 Benefits for Self-Funded or Fully Insured Employers
  • Repackaging: A “Traditional” Pharmacy Benefit Manager’s Black Box Tactic [Video]
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • National Health Expenditure Projections 2013-2023
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Generic Drug Field Full of Pricing Traps
  • Reference Pricing: Pharmacy Invoice Cost (ACTUAL) for Top Selling Generic and Brand Prescription Drugs
  • Can Specialty Pharmacies Ease the Pain Of Soaring Deductibles?
November (4)
  • 5 Strategies for Managing Specialty Prescription Drug Costs
  • Illustrative Example of Supply Chain Pricing for Brand Name Prescription Drugs
  • Plan Controls Respond to PBM Spreads, Generic Cost Spikes
  • We Need More Transparency on the Cost of Specialty Drugs
December (5)
  • PBM Myth: The Request For Proposal (RFP) Binds Your Pharmacy Benefits Manager
  • Bitter Pill: Drugs Work But Drive Overall Cost
  • The Rising Cost of Generic Prescription Drugs is Even Puzzling Experts
  • Pressing for PBM Transparency
  • The Growing Turf War over Who Can Fill Prescriptions
2013 (56)
January (3)
  • THE FEDERAL GOVERNMENT HAS DELAYED THE EXCHANGE NOTIFICATION REQUIREMENT
  • U.S. Pharmacy Distribution & Reimbursement System
  • Agencies Offer Guidance on PPACA Taxes, Fees
February (3)
  • PBMs | All about the Benjamins
  • State-by-State Health Insurance Exchange Decisions
  • Why are Prescription Drugs so Darn Expensive?
March (3)
  • How to Control Specialty Pharmacy Costs?
  • The #1 Way to Cut Employer Prescription Drug Costs
  • Infographic: The Savings Potential of Self-Insuring
April (2)
  • Small Pharmacies Getting Squeeze from Goliath PBMs
  • Insurance Commissioner Refuses to Enforce Obamacare
May (4)
  • PPACA Play-or-Pay Decision Guide for Employers
  • After CMS Releases Chargemaster Data, Hospitals Mull Price Changes
  • A Federal Agency (CMS) has Requested Copies of our Purchase Invoices for Wholesale Prescription Drugs
  • New Report Shows Drugstore Lobby Agenda Raises Rx Costs for Small Businesses and Government Programs
June (4)
  • Are Employers the Culprits Behind High U.S. Health Care Prices?
  • Medication Adherence Infographic: Getting America to Take Its Medicine
  • Spending on Specialty Medications Will Rise 67%: Report
  • U.S. Medical Price Tag Far Higher Than Others
July (4)
  • Why the Fervor Over Drug Adherence?
  • Diabetes Drugs will Lead Specialty Category
  • Evolving Definition: What is a Specialty Pharmacy?
  • Expiring Prescription Drug Patents Benefit Consumers
August (5)
  • Specialty Drug Users May Feel Co-pay Pain
  • States Scramble to Drive Down Medicaid Drug Costs
  • Without action, a one-way ticket to rising drug costs
  • Video: Specialty Drugs are a Critical Focus for Payers
  • MCOs’ Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
September (7)
  • As Specialty Injectable Drug Sales Grow, Drug-Device Collaborations change the Competitive Landscape
  • TransparentRx Thursday: Acquisition (Pharmacy) Cost for Top Selling Generic and Brand Prescription Drugs
  • Fewer Employers Plan to Offer Retiree Prescription Drug Plans
  • TransparentRx Thursday: Acquisition (Pharmacy) Cost for Top Selling Generic and Brand Prescription Drugs
  • Employers Unhappy with Their Brokers
  • TransparentRx Thursday: Acquisition (Pharmacy) Cost for Top Selling Generic and Brand Prescription Drugs
  • Infographic: Are your Pharmacy Benefit Manager’s Goals Aligned with Yours?
October (8)
  • “Actual” Acquisition Costs (what pharmacy pays) of Top Selling Generic and Brand Prescription Drugs for Payers
  • “Actual” Acquisition Costs (what pharmacy pays) of Top Selling Generic and Brand Prescription Drugs for Payers
  • The High Price of Specialty Drugs: Whining Won’t Solve the Problem!
  • “Actual” Acquisition Costs (what pharmacy pays) of Top Selling Generic and Brand Prescription Drugs for Payers
  • 7 Steps for Effectively Managing Costs of Specialty Drugs
  • “Actual” Acquisition Costs of Top Selling Generic and Brand Prescription Drugs for Payers
  • Moves by Walgreens, Other Employers to Private Exchanges Create PBM Uncertainty
  • TransparentRx Thursday: Acquisition (Pharmacy) Cost for Top Selling Generic and Brand Prescription Drugs
November (7)
  • Prescription Drug Prices: 10 Definitions All Payers $hould Know
  • “Actual” Acquisition Costs (what pharmacy pays) of Top Selling Generic and Brand Prescription Drugs: for Payers
  • Pharmacy Benefits: Eight Ways it May Unfold in 2014
  • “Actual” Acquisition Costs (what pharmacy pays) of Top Selling Generic and Brand Prescription Drugs: for Payers
  • The Next BIG Thing in Prescription Drugs is in Your Pocket!
  • “Actual” Acquisition Costs (what pharmacy pays) of Top Selling Generic and Brand Prescription Drugs for Payers
  • Hospital helps patients manage medications, even after hospital stay
December (6)
  • Pharmacy Invoice Prices (Actual) for Top Selling Generic and Brand Prescription Drugs
  • Adviser or Broker – which standard is most beneficial to plan sponsors?
  • Resource for Payers: Acquisition Cost (pharmacy invoice) for Popular Brand & Generic Prescription Drugs
  • Payers: Know Your Prescription Drug Opportunity Costs
  • “Actual” Acquisition Costs (what pharmacy pays) of Top Selling Generic and Brand Prescription Drugs: for Payers
  • Some Patients Need Help with Medication Adherence from Pharmacists
2012 (40)
January (5)
  • HHS High Risk Pools Remove Restrictions and Lowers…
  • Fiduciary: An Appropriate Role for a PBM
  • Hidden Cash Flows and Pharmacy Benefit Managers
  • Pharmacy Benefits Manager (PBM): Traditional vs. Fiduciary
  • The Lover’s Quarrel: Walgreens vs. Express Script
February (3)
  • Pharmacy Benefits Management Glossary of Terms
  • 10 Questions to Ask your Pharmacy Benefit Manager
  • What is a spread? Certainly not a Topping for Toast.
March (4)
  • A Cobra Exemption…
  • In a RFP the Whole is Greater than the Sum of its Parts
  • Service is an Attitude…Tips for Evaluating Brokers
  • Targeted for Termination? You be the Judge
April (3)
  • Dig Deeper: Don’t be Fooled by Fancy Titles and Terms
  • Informed Health Care Decisions Cut Costs & Saves Lives
  • Express Scripts & Medco Merger Approved, Now What?
May (4)
  • The Message Out of Express Script’s C-suite is Changing
  • Out-of-Network Benefits, the One–Two Punch
  • Physicians Evaluate PPACA
  • U.S. Health Insurers to Reimburse $1.3 Billion
June (3)
  • What the Healthcare Ruling really Means to Employers
  • Defragmentation: The Net Effect of Healthcare Reform
  • Rent-Seeking: A Traditional PBM’s Pathway to Riches
July (3)
  • Which side of the Fence are you on?
  • Healthcare Reform – Full Speed Ahead!
  • HSA vs. HRA: What are the Differences?
August (3)
  • Two Ways to Avoid Paying a Premium for PBM Services
  • Medicare Part D Deadline: October 15
  • PPACA: Employer Healthcare Coverage Mandate
September (2)
  • 5 New Ways to Cut Employer Prescription Drug Costs
  • The Truth about Prescription Drug Discount Cards
October (4)
  • Telemedicine: a Step in the Right Direction
  • Health Insurers and the classic “Bait and Switch”
  • PBMs: Traditional vs Fiduciary Repricing Report (Actual)
  • Get your Hand out of my Pocket!
November (3)
  • Generic Prescription Drugs by Mail can be a Bad Deal
  • Healthcare Reform: “A Peek at the Cost”
  • It’s News to me!
December (3)
  • What are Affordable Care Organizations (ACOs)?
  • An Uncertain Future: Healthcare Reform Moves Forward
  • 9 Key Questions to Ask Your Potential (new) PBM
2011 (2)
December (2)
  • PPACA: Imposes Obligations on Self-Insured Health Plans
  • Proposed ESI (Express Scripts Inc.) and Medco Health Solutions Inc. Merger

inc500

CPBS Information

  • Testimonials
  • FAQs
  • In-Person Workshop
  • Syllabus
  • Free Webinar
  • Supervisor Letter (CPBS eLearning)
  • Supervisor Letter (CPBS Workshop)
  • Recertification

More Services

  • TransparentRx (PBM)
  • CPBS
  • InsourceRx
  • PBIA
  • PrescriptionGiant
  • TransparentPAP™
  • TransparentPA™
Tyrone Education-Badge

Subscribe To Our Newsletter

Subscribe to our newsletter and receive occasional, important pharmacy benefit news and trend updates. 10,000 readers  can’t be wrong.

    vet100 seal 2024

    General Information

    • Contact Us
    • Careers
    • Blog
    • RFP Services
    • Formulary
    • Affiliates
    • PBM Services
    • 10845 Griffith Peak Drive
      Las Vegas, NV 89135
    • (866) 499-1940 (main)
    • (775) 432-6262 (sales)
    • sales@transparentrx.com
    Facebook Linkedin Youtube Rss

    CPBS Information

    • Testimonials
    • FAQs
    • In-Person Workshop
    • Syllabus
    • Free Webinar
    • Supervisor Letter (CPBS eLearning)
    • Supervisor Letter (CPBS Workshop)
    • Recertification

    More Services

    • TransparentRx (PBM)
    • CPBS
    • InsourceRx
    • PBIA
    • PrescriptionGiant
    • TransparentPAP™
    • TransparentPA™

    Subscribe To Our Newsletter

    Subscribe to our newsletter and receive occasional, important pharmacy benefit news and trend updates. 10,000 readers  can’t be wrong.

      General Information

      • Contact Us
      • Careers
      • Blog
      • RFP Services
      • Formulary
      • Affiliates
      • PBM Services
      • 10845 Griffith Peak Drive
        Las Vegas, NV 89135
      • (866) 499-1940 (main)
      • (775) 432-6262 (sales)
      • sales@transparentrx.com
      Facebook Linkedin Youtube Rss
      © Copyright - TransparentRx. All Rights Reserved. | Privacy Policy
      • About
      • Members
        • Member Portal
        • Member Portal Tutorial
        • Discount Rx Card
        • FAQs
        • Formulary
        • Mail Registration Form
        • Prior Authorization
        • Reimbursement Form
      • Clients
        • Case Study
        • CPBS Certification
        • DIY Data Analytics
        • Fiduciary PBM
        • Get a Quote
        • Savings Calculator
        • Self-Assessment
        • Transition Guide
        • White Papers
      • Events
      • Blog
      • Contact Us
      • (866) 499-1940
      error: Content is protected !!

        Sign up for email

        Over 10,000 subscribers can't be wrong!


        Subscribe to our newsletter and receive occasional, important pharmacy benefit news and trend updates.

        https://transparentrx.com/wp-content/uploads/2021/06/trx.mp4

        We use cookies to ensure that we give you the best experience on our website.
        If you continue to use this site we will assume that you are happy with it.

        AcceptPrivacy Policy